Vertex Doesn't Seem To Have Engaged With Other Players Before Alpine Deal -- Market Talk

1454 ET - Vertex Pharmaceuticals seems not to have explored alternatives before its deal for kidney-disease treatment developer Alpine. Evercore ISI analysts Liisa Bayko and Jingming Chen say in a res

WSJApr 24 02:54

Could This Stock Be the Next Biotech Buyout?

Yahoo FinanceApr 13 17:29

Insider Sells at Vera Therapeutics Inc: SVP, Finance, Chief Accounting Officer Joseph Young ...

Yahoo FinanceApr 13 07:01

Vera Therapeutics(VERA.US) Officer Sells US$228.56K in Common Stock

$Vera Therapeutics(VERA.US)$ Officer Young Joseph R sold 5,714 shares of common stock on Apr 10, 2024 at an average price of $40 for a total value of $228.56K.Source: Announcement What is statement of

Futu NewsApr 13 04:41

Vertex Pharmaceuticals to Buy Alpine Immune Sciences in $4.9B Deal

Yahoo FinanceApr 12 04:29

Vertex's Alpine Acquisition: Unpacking Analyst Predictions on Povetacicept's Potential Impact

On Wednesday, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) agreed to acquire Alpine Immune Sciences Inc (NASDAQ:ALPN) for $65 per share or approximately $4.9 billion in cash. Evercore notes the d

BenzingaApr 12 02:47